Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 5/20 | 0.50 |
| ▸ | APLNR | P35414 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20871285 | 0.92 | TAAR1 (0.57) | TAAR1APLNRSLC6A4PYCR1HTT | |
| SCHEMBL22340667 | 0.87 | APP (0.46) | TAAR1APPAPLNRSLC6A4PYCR1 | |
| SCHEMBL22340686 | 0.86 | TAAR1 (0.52) | TAAR1APLNRSLC6A4CNR1CNR2 | |
| SCHEMBL20871284 | 0.86 | TAAR1 (0.52) | TAAR1APLNRSLC6A4CNR1CNR2 | |
| SCHEMBL29335354 | 0.84 | BCL2A1 (0.52) | TAAR1APLNRSMN1; SMN2CNR2ALDH1A1 | |
| SCHEMBL29335353 | 0.84 | TAAR1 (0.51) | TAAR1APLNRSLC6A4HTTCNR1 | |
| SCHEMBL20871276 | 0.84 | TAAR1 (0.51) | TAAR1APLNRSLC6A4PYCR1ALDH1A1 | |
| SCHEMBL22340961 | 0.84 | APP (0.44) | TAAR1APPAPLNRSLC6A4PYCR1 | |
| SCHEMBL11669812 | 0.84 | TAAR1 (0.54) | TAAR1CNR1CNR2ALDH1A1 | |
| SCHEMBL29335346 | 0.82 | BMP1 (0.50) | TAAR1APLNRSLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3707132-B1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | UNIV PARIS SACLAY (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | Universite Paris-Saclay (FR) | 2021-06-15 | — | — | US | disclosed |
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | Universite Paris-Saclay (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | ADH1C, ADH1A, ADH5 | TAAR1 13/4885APP 4003/4885APLNR 3099/4885 |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | ADH1C, PNMT, ADH1A | TAAR1 23/4885APP 4157/4885APLNR 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.